QDEL Quote, Financials, Valuation and Earnings

Baxter International has a net margin of -25.21% compared to QuidelOrtho's net margin of -18.6%. QuidelOrtho's return on equity of -58.1% beat Baxter International's return on equity of -8.24%.

QuidelOrtho has a consensus price target of $51.14, signalling upside risk potential of 41.59%. On the other hand Baxter International has an analysts' consensus of $40.04 which suggests that it could grow by 15.76%. Given that QuidelOrtho has higher upside potential than Baxter International, analysts believe QuidelOrtho is more attractive than Baxter International.

QuidelOrtho has a beta of 0.097, which suggesting that the stock is 90.311% less volatile than S&P 500. In comparison Baxter International has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.696%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.66% to investors and pays a quarterly dividend of $0.17 per share. QuidelOrtho pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

QuidelOrtho quarterly revenues are $707.8M, which are smaller than Baxter International quarterly revenues of $2.8B. QuidelOrtho's net income of -$178.4M is higher than Baxter International's net income of -$512M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.87x versus 1.38x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -25.21% compared to QuidelOrtho's net margin of --. QuidelOrtho's return on equity of -58.1% beat Perspective Therapeutics's return on equity of --.

QuidelOrtho has a consensus price target of $51.14, signalling upside risk potential of 41.59%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 501.43%. Given that Perspective Therapeutics has higher upside potential than QuidelOrtho, analysts believe Perspective Therapeutics is more attractive than QuidelOrtho.

QuidelOrtho has a beta of 0.097, which suggesting that the stock is 90.311% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

QuidelOrtho quarterly revenues are $707.8M, which are larger than Perspective Therapeutics quarterly revenues of --. QuidelOrtho's net income of -$178.4M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.87x versus 13.99x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex has a net margin of -25.21% compared to QuidelOrtho's net margin of -17.18%. QuidelOrtho's return on equity of -58.1% beat Teleflex's return on equity of 1.57%.

QuidelOrtho has a consensus price target of $51.14, signalling upside risk potential of 41.59%. On the other hand Teleflex has an analysts' consensus of $168.21 which suggests that it could grow by 22.15%. Given that QuidelOrtho has higher upside potential than Teleflex, analysts believe QuidelOrtho is more attractive than Teleflex.

QuidelOrtho has a beta of 0.097, which suggesting that the stock is 90.311% less volatile than S&P 500. In comparison Teleflex has a beta of 1.211, suggesting its more volatile than the S&P 500 by 21.134%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex offers a yield of 0.99% to investors and pays a quarterly dividend of $0.34 per share. QuidelOrtho pays -- of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

QuidelOrtho quarterly revenues are $707.8M, which are smaller than Teleflex quarterly revenues of $795.4M. QuidelOrtho's net income of -$178.4M is lower than Teleflex's net income of -$136.7M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Teleflex's PE ratio is 96.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.87x versus 2.13x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -25.21% compared to QuidelOrtho's net margin of -10.04%. QuidelOrtho's return on equity of -58.1% beat Xtant Medical Holdings's return on equity of -35.34%.

QuidelOrtho has a consensus price target of $51.14, signalling upside risk potential of 41.59%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 259.34%. Given that Xtant Medical Holdings has higher upside potential than QuidelOrtho, analysts believe Xtant Medical Holdings is more attractive than QuidelOrtho.

QuidelOrtho has a beta of 0.097, which suggesting that the stock is 90.311% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

QuidelOrtho quarterly revenues are $707.8M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. QuidelOrtho's net income of -$178.4M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 0.87x versus 0.56x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.